AUTHORS
Rebecca Silbermann, MD, Al-Ola Abdallah, MD2, Attaya Suvannasankha, MD3, Emily Zyborowicz, MPH4, Jeffrey Carter5, Chelsie Anderson Chadha6, Laura Simone, PhD7, Shelby Sullivan, PharmD8
AFFILIATIONS
1 Oregon Health & Science University, Portland, Oregon, United States
2 University of Kansas Medical Center, Kansas City, Kansas, United States
3 Indiana University School of Medicine, Indianapolis, Indiana, United States
4 PRIME Education, New York, New York, United States
5 PRIME Education, New York, New York, United States
6 PRIME Education, New York, New York, United States
7 PRIME Education, New York, New York, United States
8 PRIME Education, New York, New York, United States
ABSTRACT
Background:
Community oncology teams are assuming a greater role in managing patients with relapsed/refractory multiple myeloma (R/R MM) who receive bispecific antibody (bsAb) therapy. For many clinics this involves coordinating transitions of care (ToC) for patients from their local academic medical center (AMC) after completing step-up dosing. However, limited knowledge and experience with bsAb therapies, including the underlying workflows and processes that support seamless ToC, continued administration and associated adverse event (AE) management inhibit optimal care delivery and patient outcomes. This multi-center initiative (Dec 2024 – May 2026) evaluated barriers to guideline- and evidence-based care for patients with R/R MM receiving bsAb therapy following their transition back into their community clinics.
Methods:
This initiative engaged 5 AMCs and 10 regionally-tethered community oncology clinics. Baseline surveys (N = 100) of care team members assessed clinic workflows and experiences related to ToC processes and AE management the community. Findings informed development of a Roadmap for bsAb Transitions resource, introduced during five audit-feedback (AF) sessions pairing AMC and their local community teams (pre/post N = 76/45) to identify practice gaps and develop improvement plans. Two refinement workshops (pre/post N = 54/32) supported continued collaboration, implementation and workflow optimization. Follow-up surveys were completed by 10 clinic champions representing the 10 participating community sites and evaluated changes in provider knowledge, process changes and performance.
Results:
At baseline, 52% of providers were unsure whether their center had a standardized protocol for transitioning patients receiving bsAbs from AMCs to community care, and 35% rated AMC-community collaboration as poor/fair. Common barriers to effective management of patients receiving bsAb therapy included limited staffing/resources (29%), AE management (27%), and coordinating continued bsAb administration (27%). Key AE management challenges included delayed/long-term toxicities (46%) and inadequate staff preparedness for cytokine release syndrome (CRS)/neurotoxicity management (29%). Providers reported paired AMC-community education (47%) and clearer AMC guidance regarding clinic roles (37%) as the most helpful to address these challenges.
Following AF sessions, knowledge of the guideline-aligned indication for bsAb increased from 30% to 67%. Priority areas for improvement included post-transition AE monitoring (67%), information sharing between practice settings (52%), and coordination of continued bsAb administration (43%). Action plans focused on standardized protocols, improved AMC-community communication, AE monitoring workflows, staff education, and patient/caregiver support.
During refinement workshops, 78% reported satisfaction with implementation progress, and confidence in supporting ToC increased from 50% to 88%. Reported practice changes included standardized monitoring protocols, nurse triage workflows, improved AMC coordination, and initiation of bsAb therapy within community clinics.
Follow-up surveys (median follow-up 6 months) demonstrated systems-level improvements. All respondents implemented and sustained standardized workflows for transitioning patients from AMC to community care following step-up dosing. Additionally, 80% reported structured AE monitoring workflows and improved coordination across care settings. Provider-reported care impacts included fewer delays in treatment continuation (40%), improved patient understanding of symptom monitoring (40%), clearer delineation of responsibilities (40%), and improved timely AE recognition and management (20%).
Conclusions:
This initiative identified persistent gaps in bsAb-related ToC, communication, and AE management in community MM care. Collaborative AF sessions, refinement workshops, and implementation of a structured ToC guide improved provider confidence, interdisciplinary collaboration, and adoption of standardized workflows supporting safe community-based bsAb delivery. These findings suggest structured AMC-community partnership models may facilitate safer, coordinated ToC for patients with MM receiving bsAb therapy.
Study Sponsor Statement
Supported by an educational grant from Janssen Biotech Inc, administered by Janssen Scientific Affairs both Johnson and Johnson companies, who had no role in the study design, execution, analysis, or reporting.
DISCLOSURES
Rebecca Silbermann, MD: Sanofi-Aventis - Research Funding; Sanofi-Aventis - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony)